Clinical trial • Phase III • Endocrinology
cagrilintide for Obesity
Phase III trial of cagrilintide for Obesity. None/Not specified-controlled. 120 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Obesity
- Trial Stage
- Phase III
- Drug Modality
- Peptide/protein/enzyme
Key dates
- Initial CTIS Submission Date
- 11-02-2026
- First CTIS Authorization Date
- 02-04-2026
Trial design
None/Not specified-controlled Phase III trial across 1 site in Germany.
- Comparator
- None/Not specified
- Target Sample Size
- 120
Recruitment
- Planned Sample Size
- 120
- Recruitment Window Months
- 15
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 120
Germany
- Earliest CTIS Part Ii Submission Date
- 16-03-2026
- Latest Decision Or Authorization Date
- 23-04-2026
- Processing Time Days
- 38
- Number Of Sites
- 1
- Number Of Participants
- 120
Sites
- Site Name
- Klinikum Westend Haus 31, Spandauer Damm 130, Charlottenburg
- Department Name
- Parexel Early Phase Unit Berlin, 101
- Contact Person Name
- Obada Al Hamdan
- Contact Person Email
- obada.alhamdan@parexel.com
Sponsor
Primary sponsor
- Full Name
- Novo Nordisk A/S
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Contract research organisations
- Name
- PAREXEL International GmbH
Investigational products
- Investigational Product Name
- cagrilintide
- Active Substance
- cagrilintide
- Modality
- Peptide/protein/enzyme
Related trials
Other published trials that may interest you.
- TIRZEPATIDE for Obesity
- RO7795068 for Obesity
- L-PHENYLALANYL-2-METHYLALANYL-L-ALFA-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-ALFA-ASPARTYL-L-VALYL-L-SERYL-L-LYSYL-L-GLUTAMINYL-L-LEUCYL-L-ALFA-GLUTAMYL-L-ALFA-GLUTAMYL-L-LYSYL-L-ARGINYL-L-VALYL-L-ARGINYL-L-ALFA-GLUTAMYL-L-PHENYLALANYL-L-ISOLEUCYL-L-ALFA-GLUTAMYL-L-TRYPTOPHYL-L-LEUCYL-L-LYSYL-L-GLUTAMINYLGLYCYLGLYCYL-L-PROLYL-L-SERYL-L-SERYLGLYCYL-L-LYSYL-L-PROLYL-L-PROLYL-L-PROLYLGLYCYL-L-LYSYL-N6-[N-(19-CARBOXY-1-OXONONADECYL)-L-GAMMA-GLUTAMYL]-L-LYSINE for Obesity
- ZENAGAMTIDE for Obesity
- TYROSYL-2-AMINOISOBUTYRYL-GLUTAMYL-GLYCYL-THREONYL-PHENYLALANYLTHREONYL-SERYL-ASPARTATE-TYROSYL-SERYL-ISOLEUCYL-TYROSYL-LYSYL([2-[2- AMINOETHOXY]ETHOXY]ACETYL-[2-[2-AMINOETHOXY]ETHOXY]ACETYL-GAMMA-GLUTAMYL-EICOSANOYL)-GLUTAMYL-LYSYL-ISOLEUCYL-ALANYL-ALANYL-GLUTAMINE-GLUTAMYL-PHENYLALANYL-VALYL-ASPARAGINE-CHROMYL-LEUCYL-LEUCYL-ALANYL-GLYCYL-GLYCYL-PROLYL-SERYL-SERYL-GLYCYL-ALANYL-PROLYL-PROLYL-PROLYL-SERYL AMIDE for Obesity